PURPOSE: To estimate the rate of visual field progression in open-angle glaucoma (OAG) subjects, by using data from population-based cross-sectional studies. METHODS: Subjects with OAG were identified in nine surveys of randomly sampled populations using standard criteria for glaucomatous optic neuropathy. Subjects were of European, African, Chinese, and Hispanic ethnicity. The measure of OAG damage was the mean deviation (MD) of an automated visual field test (Humphrey Field Analyzer; Carl Zeiss Meditec, Inc., Dublin, CA). The rate of progression was the mean of all subjects' damage in the worse eye divided by an average time since onset. Time since onset was estimated from age-specific prevalence rates. RESULTS: A total of 1066 subjects with OAG contributed visual field data. The mean worsening in decibels per year was: European-derived, -1.12; Hispanic, -1.26; African-derived, -1.33; and Chinese -1.56 (difference among ethnicities, P = 0.16). The mean duration of disease was lowest among Chinese persons at 10.5 years (95% CI: 8.8-12.6) and was highest in African-derived subjects at 15.4 years (95% CI: 14.6-15.9). The progression rate was not consistently related to age or gender. By combining disease duration and progression rate, the model predicted that 15% or fewer of the worse eyes would reach the end of the field damage scale in the patient's lifetime. CONCLUSIONS: The estimates of typical worsening per year in the worse eye among subjects with OAG suggested slightly more rapid progression than in some clinic-based studies. The rate did not differ significantly by ethnicity or gender, but was worse in those with known, treated OAG and in pseudophakic subjects.
PURPOSE: To estimate the rate of visual field progression in open-angle glaucoma (OAG) subjects, by using data from population-based cross-sectional studies. METHODS: Subjects with OAG were identified in nine surveys of randomly sampled populations using standard criteria for glaucomatous optic neuropathy. Subjects were of European, African, Chinese, and Hispanic ethnicity. The measure of OAG damage was the mean deviation (MD) of an automated visual field test (Humphrey Field Analyzer; Carl Zeiss Meditec, Inc., Dublin, CA). The rate of progression was the mean of all subjects' damage in the worse eye divided by an average time since onset. Time since onset was estimated from age-specific prevalence rates. RESULTS: A total of 1066 subjects with OAG contributed visual field data. The mean worsening in decibels per year was: European-derived, -1.12; Hispanic, -1.26; African-derived, -1.33; and Chinese -1.56 (difference among ethnicities, P = 0.16). The mean duration of disease was lowest among Chinese persons at 10.5 years (95% CI: 8.8-12.6) and was highest in African-derived subjects at 15.4 years (95% CI: 14.6-15.9). The progression rate was not consistently related to age or gender. By combining disease duration and progression rate, the model predicted that 15% or fewer of the worse eyes would reach the end of the field damage scale in the patient's lifetime. CONCLUSIONS: The estimates of typical worsening per year in the worse eye among subjects with OAG suggested slightly more rapid progression than in some clinic-based studies. The rate did not differ significantly by ethnicity or gender, but was worse in those with known, treated OAG and in pseudophakic subjects.
Authors: Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass Journal: Arch Ophthalmol Date: 2002-06
Authors: M Roy Wilson; Omofolasade Kosoko; Claude L Cowan; Pamela A Sample; Chris A Johnson; Gleb Haynatzki; Cheryl Enger; David Crandall Journal: Am J Ophthalmol Date: 2002-09 Impact factor: 5.258
Authors: Steven M Kymes; Dennis L Lambert; Paul P Lee; David C Musch; Carla J Siegfried; Sameer V Kotak; Dustin L Stwalley; Joel Fain; Chris Johnson; Mae O Gordon Journal: Ophthalmology Date: 2012-04-25 Impact factor: 12.079
Authors: Pradeep Y Ramulu; Eugenio Maul; Chad Hochberg; Emilie S Chan; Luigi Ferrucci; David S Friedman Journal: Ophthalmology Date: 2012-03-02 Impact factor: 12.079
Authors: Dolly S Chang; Karun S Arora; Michael V Boland; Wasu Supakontanasan; David S Friedman Journal: Am J Ophthalmol Date: 2013-09-04 Impact factor: 5.258
Authors: Joan M O'Brien; Rebecca J Salowe; Raymond Fertig; Julia Salinas; Maxwell Pistilli; Prithvi S Sankar; Eydie Miller-Ellis; Amanda Lehman; Windell H A Murphy; Melissa Homsher; Katelyn Gordon; Gui-Shuang Ying Journal: Am J Ophthalmol Date: 2018-03-17 Impact factor: 5.258